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Background: Cancer stem cells (CSCs) are considered responsible for the recurrence and chemoresistance of cancer.
Dysregulated autophagy is highly prevalent in many types of cancer including pancreatic cancer and has been
implicated in cytoprotection and tumor promotion. This study aimed to investigate the role of autophagy in regulating
cancer stemness and chemoresistance of pancreatic cancer.
Methods: The correlation between autophagy and CSCs and its clinical significance were analyzed using pancreatic
cancer tissue microarrays. Genetic and pharmacological approaches were applied to explore the function of autophagy
on CSC activity and gemcitabine resistance of pancreatic cancer cells in vitro and in vivo.
Results: LC3 expression positively correlated with the expression of CSC markers aldehyde dehydrogenase 1 (ALDH1),
CD44, and CD133 in pancreatic cancer tissues. High coexpression of LC3/ALDH1 was associated with both poor overall
survival and progression-free survival. In pancreatic cancer cell lines, higher LC3-II expression was observed in the
sphere-forming cells than in the bulk cells. Blockade of autophagy by silencing ATG5, ATG7, and BECN1 or the
administration of autophagy inhibitor chloroquine markedly reduced the CSC populations, ALDH1 activity, sphere
formation, and resistance to gemcitabine in vitro and in vivo. Furthermore, osteopontin (OPN) was found to stimulate
LC3-II, ALDH1, CD44, and CD133 expression in PANC-1 cells, whereas this effect could be prevented by OPN
knockdown and autophagy blockade. After treatment with various inhibitors against the major signaling pathways
downstream of OPN, only the inhibitor of NF-κB activation, BAY 1170–82, could effectively counteract OPN-induced
autophagy and CSC activity. According to the histochemical results, pancreatic cancer patients manifesting high levels
of OPN/LC3/ALDH1 and OPN/CD44/CD133 had poor survival.
Conclusions: Induction of autophagy mediated by OPN/NF-κB signaling is required for maintenance of pancreatic CSC
activity. Combination of gemcitabine with pharmacological autophagy inhibitors is a promising therapeutic strategy for
pancreatic cancer.
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The cancer stem cell (CSC) theory postulates that
tumors may arise from a small fraction of cancer cells that
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have been linked to CSCs, revealing new opportunities for
cancer treatment [2–4]. Pancreatic CSCs have been identi-
fied by several putative markers, such as CD44, CD24,
EpCAM, CD133, and aldehyde dehydrogenase 1 (ALDH1)
[5–7]. The presence of CSCs in pancreatic cancer was
associated with poor patient outcomes [8]. Pancreatic
tumors containing higher percentage of CSCs displayed
enhanced chemoresistance and metastatic activity [6, 9,
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treatment.
Autophagy is a cellular self-degradation process that
is required to maintain cell homeostasis. Alterations in
autophagy-related signaling pathways frequently occur
in many human diseases, including cancer [11]. Consid-
erable evidence has supported that autophagy maintains
the survival of cancer cells through conferring stress tol-
erance and limiting damages [12]. In pancreatic cancer,
sustained activation of autophagy is associated with
poor survival [13]. Genetic or pharmacologic abrogation
of autophagy suppressed the growth of pancreatic
cancer cells in vitro and led to tumor regression in vivo
due to autophagy inhibition-mediated reactive oxygen
species production, DNA damages and altered cell me-
tabolism [14]. Therefore, autophagy is required for pan-
creatic cancer progression. Because autophagy acts as a
survival pathway in cells under stress, much attention
has been paid to the role of autophagy in CSC biology.
Genetic inhibition of autophagy reduced the proportion
of breast cancer cells bearing a CD44+/CD24-/low CSC-
like phenotype, suggesting the role of autophagy in
maintaining the typical breast CSCs [15]. Blockade of
both autophagy flux and lysosomal proteolyic activity by
K+/H+ ionophore Salinomycin effectively reduced the
population of ALDH+ breast CSCs [16]. Treatment with
the autophagy inhibitor chloroquine (CQ) strongly pro-
moted γIR-induced cell death in highly radioresistant
patient-derived stem-like glioma cells [17]. In pancreatic
cancer cells, high levels of autophagy have been ob-
served under basal conditions [14, 18]; however, the re-
lation between autophagy and pancreatic CSCs remains
to be explored.
Osteopontin (OPN), a secreted glycoprotein, has
been implicated in a variety of physiological and patho-
physiological processes, such as bone remodeling,
angiogenesis, immunity, atherosclerosis, and cancer
progression [19, 20]. By interacting with CD44 family
of receptors or integrin αvβ3, OPN can activate several
downstream signaling pathways, such as PI3K/AKT,
NF-κB, and MEK/ERK [21]. OPN overexpression in
many types of cancer has been considered a poor prog-
nostic marker [22]. Recently, increased OPN expres-
sion has been observed in sphere-growing stem-like
cells of pancreatic cancer compared with their adher-
ent counterpart [23]. OPN overexpression significantly
increased the formation of spheres derived from the
brain tumor cells of p53/PTC double heterozygous
mice [24], suggesting a role of OPN in regulating CSC
activity. Given that OPN can induce autophagy directly
through integrin/CD44 and p38 MAPK-mediated path-
ways in vascular smooth muscle cells [25], we sought
to investigate whether OPN can increase pancreatic
CSC activity through stimulation of autophagy.Results
CSC markers colocalize with the autophagy protein LC3 in
pancreatic cancer cells
To determine the relationship between autophagy and
CSCs, we performed an immunofluorescence study in
tissue microarrays (TMAs) of 93 pancreatic tumors and
calculated the correlation coefficients between LC3 and
CSC marker expression. Autophagy was demonstrated
by LC3 puncta in cells expressing ALDH1, CD44, and
CD133 (Fig. 1a). LC3 colocalized with LAMP1, a lyso-
somal marker used for detection of LC3+/LAMP1+ auto-
lysosome formation [26], in pancreatic tumor tissues,
and SQSTM1/p62, an autophagy marker that is de-
graded during autophagy [26], was weakly stained in
cells expressing LC3, revealing the activation of autophagy
in pancreatic cancer cells (Additional file 1: Figure S1A).
LC3 expression positively showed significant correlations
with ALDH1, CD44, and CD133 expression (R = 0.849
with P < 0.001, R = 0.309 with P < 0.01, and R = 0.289 with
P < 0.01, respectively; Fig. 1b). To confirm the immuno-
fluorescence results, we next compared LC3 expression
between CSCs and bulk cells in human pancreatic cancer
cell lines and primary tumor-derived cells. Pancreatic
CSCs were enriched by sphere formation and were
characterized by elevated expression of CSC markers
and embryonic stem cell transcription factors (SOX2
and NANOG) that are involved in the regulation of
CSC functions [27] (Fig. 1c), chemoresistance, and
anti-apoptosis (Additional file 2: Figure S2A and S2B).
Enriched CSCs harvested from spheres exhibited
higher LC3-II expression levels than the bulk cells did
(Fig. 1c). Transmission electron microscopy images
also showed increased autophagosome-like double-
membrane structures in PANC-1 CSCs as compared
with the bulk cancer cells (Additional file 1: Figure S1B).
These results demonstrate that autophagic activity is
upregulated in pancreatic CSCs.
High LC3/ALDH1 coexpression confers a poor prognosis
in pancreatic cancer patients
With the purpose of understanding the prognostic asso-
ciation among autophagy, pancreatic CSCs, and patient
survival, the expression levels of LC3 and ALDH1 were
detected by immunofluorescence staining and the sur-
vival probability were analyzed using the Kaplan-Meier
method. Neither LC3 expression nor ALDH1 expression
showed a statistically significant correlation with patient
outcomes (Additional file 3: Figure S3A and S3B). How-
ever, patients with high expression levels of LC3 and
ALDH1 simultaneously in pancreatic tumor cells dem-
onstrated worse overall survival (OS) and disease-free
survival (DFS) (P = 0.046 and P = 0.008; Fig. 1d), suggest-
ing that coexpression of LC3/ALDH1 is a more specific
prognostic marker for pancreatic cancer than is
Fig. 1 (See legend on next page.)
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Fig. 1 Autophagy marker LC3 expression correlates with CSC marker expression in pancreatic cancer cells. a Pancreatic tumor tissues were
immunofluorescently stained for autophagy marker LC3 (green) and CSC markers ALDH1, CD44, and CD133 (red). Samples stained with secondary
antibodies alone served as a negative control. Magnification: 800×, scale bar: 20 μm. b Immunofluorescence analysis of LC3, ALDH1, CD44, and
CD133 was performed in TMAs. LC3 expression showed a significant positive correlation with ALDH1 (R= 0.849, P< 0.001), CD44 (R= 0.309, P= 0.003), and
CD133 expression (R= 0.289, P= 0.005). c PANC-1, MIA PaCa-2, AsPC-1, and SP-1 cells were cultured in ultra-low attachment plates for 14 days to form
spheres. The lysates of sphere-forming cells were collected for Western blotting with the indicated antibodies. β-Actin was used as a loading control. The
levels of LC3-II were normalized against β-Actin. Values represent the means ± SE of three independent experiments. *, P< 0.05; **, P< 0.01; ***, P< 0.001,
vs. bulk cells. d Kaplan–Meier analysis showed that high levels of LC3/ALDH1 were significantly associated with poor OS (P= 0.046) and DFS (P= 0.008)
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respect to LC3/ALDH1 coexpression are outlined in
Table 1. High LC3/ALDH1 coexpression significantly
correlated with survival and recurrent status (P = 0.001
and P = 0.000; Table 1). Multivariate analysis showed
that high LC3/ALDH1 coexpression is an independent
prognostic factor for OS and DFS (hazard ratio = 4.721
with P = 0.004 and hazard ratio = 6.597 with P = 0.000;
Table 2).
Autophagy blockade reduces pancreatic CSC activity
To determine the role of autophagy in pancreatic cancer
stemness, we established lentivirus-mediated stable
ATG5, ATG7, and BECN1 knockdown cell lines shATG5,
shATG7, and shBECN1 derived from PANC-1 cells and
analyzed their CSC activity. Knockdown efficiencies were
determined by Western blotting. The protein expression
of CD44, CD133, and ALDH1 was found to be signifi-
cantly decreased in shATG5, shATG7, and shBECN1
cells (Fig. 2a). Flow cytometry analysis showed that
LC3+/ALDH1+ cells comprised 4.6 % of PANC-1 control
cells; however, silencing ATG5, ATG7, and BECN1
decreased the percentages of LC3+/ALDH1+ cells to 0.2,
0.1, and 0.2 %, respectively. Similarly, the percentages of
CD44+/CD133+ cells were also reduced to 1.0 % in
shATG5 cells, 0.3 % in shATG7 cells, and 0.2 % in
shBECN1 cells when compared with 4.1 % in PANC-1
control cells (Fig. 2b). Because ALDH1 activity is a
critical feature of CSCs, we performed the ALDEFLUOR
assay to examine the effect of autophagy blockade on
ALDH1 activity. In comparison with 4.8 % in PANC-1
control cells, the percentages of cells possessing ALDH1
activity was reduced to 1.7 % in shATG5 cells, 2.4 % in
shATG7 cells, and 2.2 % in shBECN1 cells (Fig. 2c). To
further examine whether autophagy blockade affects the
self-renewal capacity of pancreatic CSCs, we performed
sphere-forming experiments. The results showed that
the number of spheres was significantly lower in
shATG5, shATG7, and shBECN1 cells than in the
control cells (Fig. 2d).
To confirm the above-mentioned results, pharmaco-
logical manipulation of autophagy in pancreatic cancer cells
was carried out. We tested whether interference withautophagy by autophagy inhibitor CQ and autophagy
inducer rapamycin affects pancreatic CSC activity. Flow
cytometry results showed that the percentage of
LC3+/ALDH1+ cells was decreased from 4.5 % in untreated
PANC-1 cells to 1.7 % by CQ treatment but was elevated
to 13.6 % by rapamycin treatment. The percentage of
CD44+/CD133+ cells was also decreased from 3.9 % in
untreated PANC-1 cells to 2.0 % by CQ treatment but was
increased to 12.1 % by rapamycin treatment (Fig. 3a). The
results of ALDEFLUOR assay showed that CQ decreased
the percentage of PANC-1 cells possessing ALDH1 activity
in the corresponding control treatment group from 4.5 to
0.8 %, but rapamycin increased it to 9.4 % (Fig. 3b). More-
over, the number of PANC-1 spheres was decreased by CQ
but was increased by rapamycin dose-dependently (Fig. 3c).
Collectively, blockade of autophagy by both genetic and
pharmacological inhibitors could markedly suppress
pancreatic CSC activity, revealing the requirement of
autophagy for CSC maintenance.Autophagy blockade prevents pancreatic cancer cell
growth and tumor formation
To address the physiological significance of autophagy in
the regulation of pancreatic CSC activity, we measured
pancreatic cancer cell growth after autophagy was
blocked. The MTT results showed that the cell growth of
shATG5, shATG7, and shBECN1 cells was downregulated
as compared with that of the control cells (Fig. 4a, left).
We next determined whether blockade of autophagy leads
to apoptosis and found that the number of apoptotic cells
was not increased in shATG5, shATG7, and shBECN1
cells (Fig. 4a, right), suggesting that the decreased cell
growth did not result from apoptosis. Because autophagy
blockade decreased pancreatic cancer cell growth in vitro,
we evaluated the effects of autophagy blockade on tumor
progression in vivo using a NOD/SCID mouse xenograft
model. Eight weeks after cell inoculation, xenografts from
shATG5, shATG7, and shBECN1 cells had lower final
tumor volume and tumor weight than did xenografts
from the control cells (Fig. 4b), revealing a positive
association between autophagic activity and pancreatic
tumor growth rates.
Table 1 Correlation between LC3/ALDH1 coexpression and
clinicopathological profiles
Characteristic Low LC3/ALDH1 High LC3/ALDH1 P
Age, median (range) 67 (38–85) 64 (37–85)
Sex
Male 37 (68.5) 23 (59.0) 0.342
Female 17 (31.5) 16 (41.0)
Tumor location
Head 28 (51.9) 29 (74.4) 0.177
Neck 5 (9.3) 2 (5.1)
Body/tail 12 (22.2) 4 (10.3)
Uncinate process 9 (16.7) 4 (10.3)
Tumor size
< 3 cm 30 (55.6) 22 (56.4) 0.935
≥ 3 cm 24 (44.4) 17 (43.6)
Lymph nodes
Negative 30 (55.6) 16 (41.0) 0.167
Positive 24 (44.4) 23 (59.0)
Margin status
R0 41 (75.9) 25 (64.1) 0.462
R1 11 (20.4) 12 (30.8)
R2 2 (3.7) 2 (5.1)
Tumor grade
Poorly diff. 11 (20.4) 6 (15.4) 0.345
Moderate diff. 25 (46.3) 24 (61.5)
Well diff. 18 (33.3) 9 (23.1)
Stage
I 10 (18.5) 1 (2.6) 0.097
II 40 (74.1) 36 (92.3)
III 3 (5.6) 1 (2.6)
IV 1 (1.9) 1 (2.6)
CA19-9
< 37U/ml 12 (22.2) 8 (20.5) 0.843
≥ 37U/ml 42 (77.8) 31 (79.5)
Adjuvant therapy
Yes 26 (48.1) 11 (28.2) 0.053
No 28 (51.9) 28 (71.8)
Diabetes mellitus
Yes 18 (33.3) 11 (28.2) 0.598
No 36 (66.7) 28 (71.8)
Survival
Yes 35 (64.8) 12 (30.8) 0.001
Table 1 Correlation between LC3/ALDH1 coexpression and
clinicopathological profiles (Continued)
No 19 (35.2) 27 (69.2)
Recurrence
Yes 26 (48.1) 35 (89.7) 0.000
No 28 (51.9) 4 (10.3)
The bold value indicates P < 0.05
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gemcitabine
Since CSCs are believed to contribute to chemoresis-
tance in cancer, we examined whether autophagy block-
ade affects gemcitabine resistance of pancreatic cancer
cells. After treatment with gemcitabine, the cell survival
rates of shATG5, shATG7, and shBECN1 cells were
lower than that of the control cells though the results
failed to show statistically significant difference between
groups (Fig. 4c, left). We next isolated sphere-forming
cells from the control, shATG5, shATG7, and shBECN1
cells to compare their resistance to gemcitabine. The cell
viability of sphere-forming cells from shATG5, shATG7,
and shBECN1 cells significantly decreased following
gemcitabine treatment compared with that of the con-
trol cells (Fig. 4c, right). To confirm the in vitro results,
pancreatic cancer cells were inoculated subcutaneously to
NOD/SCID mice followed by the administration of gemci-
tabine when the tumor volume reached 62.5 mm3. Com-
pared with a decline of 48 % in the tumor volume of mice
inoculated with the control cells, gemcitabine could mark-
edly reduce the tumor volumes by 91, 87, and 96 % in mice
inoculated with shATG5, shATG7, and shBECN1 cells,
respectively (Fig. 4d). Furthermore, a combined treatment
of CQ and gemcitabine was more effective than was either
agent alone in preventing pancreatic tumor formation
(Fig. 4e). Therefore, autophagy blockade boosted the
susceptibility of pancreatic CSCs to gemcitabine and thus
enhanced the efficacy of gemcitabine against pancreatic
cancer.
OPN upregulates pancreatic CSC activity by activating
autophagy
OPN has been reported to upregulate the sphere-forming
capability of tumor cells [23, 24]. In addition, OPN can
stimulate autophagy directly through the integrin/CD44
and p38 MAPK-mediated pathways in vascular smooth
muscle cells [25]. Therefore, we hypothesized that OPN
may upregulate CSC activity by activating autophagy.
Confocal immunofluorescence results demonstrated
that OPN treatment increased the number of ALDH1-
expressing cells with upregulated LC3 puncta in
PANC-1 cells, MIA PaCa-2 cells, and SP-1 primary
pancreatic tumor cells. Blockade of autophagy by CQ
led to LC3 puncta accumulation but prevented OPN-
Table 2 Outcomes of assessable patients with pancreatic cancer according to protein expression
Variable Overall survival Disease-free survival
HR 95 % CI P HR 95 % CI P
LC3
Low (n = 50) 1 0.087–0.589 0.200 1 0.251–1.387 0.226
High (n = 43) 0.227 0.590
ALDH1
Low (n = 51) 1 0.516–3.684 0.522 1 0.315–1.481 0.335
High (n = 42) 1.378 0.684
LC3/ALDH1
Low (n = 54) 1 1.622–13.739 0.004 1 2.535–17.170 0.000
High (n = 39) 4.721 6.597
OPN
Low (n = 58) 1 0.233–2.430 0.634 1 0.442–4.234 0.587
High (n = 35) 0.752 1.368
OPN/LC3/ALDH1
Low (n = 42) 1 Reference 1 Reference
Moderate (n = 28) 1.770 0.846–3.704 0.130 1.351 0.773–2.362 0.291
High (n = 23) 2.385 1.129–5.038 0.023 2.245 1.183–4.259 0.013
OPN/CD44/CD133
Low (n = 39) 1 Reference 1 Reference
Moderate (n = 42) 1.929 0.897–4.146 0.093 1.639 0.889–3.021 0.113
High (n = 12) 4.527 1.403–14.604 0.011 4.140 1.672–10.254 0.002
The bold value indicates P < 0.05
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S4A). Knockdown of OPN significantly suppressed cell
growth (Additional file 3: Figure S3B), sphere forma-
tion (Additional file 4: Figure S4D), and tumor forma-
tion (Additional file 4: Figure S4E), but promoted
apoptosis (Additional file 4: Figure S4C). The biochem-
ical results showed that OPN induced LC3-II, ALDH1,
CD44, and CD133 expression in PANC-1 cells (Fig. 5a),
whereas knockdown of OPN decreased their expression
(Fig. 5b). Blockade of autophagy by silencing ATG5,
ATG7, and BECN1 could hinder OPN-mediated upregula-
tion of ALDH1, CD44, and CD133 (Fig. 5c). These find-
ings demonstrated that OPN increased pancreatic CSC
activity by activating autophagy. OPN exerts its biological
functions by triggering multiple downstream signaling
pathways, such as PI3K/AKT, NF-κB, MEK/ERK, STAT3,
JNK, and p38 MAPK [21, 28, 29]. We therefore attempted
to determine the major signaling pathway that mediates
OPN-activated autophagy. In both PANC-1 and MIA
PaCa-2 cells, the NF-κB, ERK, and STAT3 signaling
pathways were activated by OPN, but AKT, JNK, and p38
MAPK were not (Additional file 5: Figure S5). To inhibit
NF-κB, ERK, and STAT3 activation, the JAK2/STAT3
inhibitor AG490, the MEK/ERK inhibitor PD98059, and the
NF-κB inhibitor BAY 1170–82 were used. Only BAY 1170–82 pretreatment could effectively block OPN-mediated
increase in LC3-II expression (Fig. 5d) and the populations
of LC3+/ALDH1+ cells and CD44+/CD133+ cells in PANC-1
cells (Fig. 5e), suggesting that OPN activated autophagy
via NF-κB to increase pancreatic cancer stemness.
Coexpression of OPN, LC3, and ALDH1 and coexpression
of OPN, CD44, and CD133 portend poor patient outcomes
To assess the correlation of OPN with LC3/ALDH1 and
CD44/CD133 coexpression in pancreatic tumor speci-
mens, we performed triple immunofluorescence staining
in TMAs. Confocal images revealed that OPN was
highly expressed in both LC3/ALDH1-expressing cells
and CD44/CD133-expressing cells (Fig. 6a, upper and
lower, respectively). OPN expression showed a positive
correlation with LC3/ALDH1 coexpression (R = 0.354
with P < 0.001) and CD44/CD133 coexpression (R = 0.211
with P < 0.05) (Fig. 6b). High levels of OPN/LC3/
ALDH1 and OPN/CD44/CD133 were associated with
poor OS (P = 0.029 and P = 0.000, respectively) and
DFS (P = 0.009 and P = 0.000, respectively) (Fig. 6c, d).
Multivariate analysis revealed that high OPN/LC3/
ALDH1 coexpression and high OPN/CD44/CD133
coexpression were independently predictive for OS
(hazard ratio 2.385 with P = 0.023 and hazard ratio
Fig. 2 (See legend on next page.)
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Fig. 2 Blockade of autophagy by genetic knockdown reduces pancreatic CSC activity. a The expression of autophagy-related proteins and CSC
markers in the PANC-1-derived cells permanently expressing shRNAs against ATG5 (shATG5), ATG7 (shATG7), and BECN1 (shBECN1) was detected
by Western blotting. The levels of LC3-II, ALDH1, CD133, and CD44, were normalized against β-Actin and presented as means ± SE of three separate
experiments. NS, not significant; ***, P < 0.001, vs. control cells. b The expression of LC3, ALDH1, CD44, and CD133 in the control, shATG5, shATG7, and
shBECN1 cells was analyzed by flow cytometry. The bar graphs indicate the percentage ± SE of LC3+/ALDH1+ cells (left) and CD44+/CD133+ cells (right).
c The enzymatic activity of ALDH1 in the control, shATG5, shATG7, and shBECN1 cells was examined by ALDEFLUOR assay. The bar graph indicates the
percentage ± SE of ALDEFLUOR+ cells in each cell line. d The bright field micrographs showed sphere formation of the control, shATG5, shATG7,
shBECN1 cells cultured in ultra-low attachment plates for 14 days. The number of spheres was calculated and presented as means ± SE. NS, not
significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared to controls
Yang et al. Molecular Cancer  (2015) 14:179 Page 8 of 174.527 with P = 0.011, respectively) and DFS (hazard
ratio 2.245 with P = 0.013 and hazard ratio 4.140 with
P = 0.002, respectively) (Table 2).
Discussion
CSCs are believed to drive the neoplastic progression,
tumor recurrence, and metastasis. A comprehensive
understanding of the biology of CSCs allows the develop-
ment of effective therapies for pancreatic cancer. In this
study, we have observed elevated levels of autophagy in
pancreatic CSCs. Autophagy blockade profoundly reduced
pancreatic CSC activity. OPN could induce autophagy by
activating NF-κB and thus upregulate pancreatic CSC
activity.
Recently, altered autophagy have been linked to CSCs.
Dormant breast cancer stem-like cells induced by farnesyl
transferase inhibitors expressed high levels of autophagy
markers, such as ATG5, ATG7, and ATG12. Blockade of
autophagy by 3-methyladenine decreased the proportion
of stem-like cells [30]. The autophagic flux was upregu-
lated in the sphere-forming breast cancer cells expressing
ALDH1 compared with the bulk population. Knockdown
of either BECN1 or ATG7 dramatically suppressed the
sphere formation of breast CSCs [31]. In pancreatic
cancer, cells with stem-like properties displayed stronger
autophagic activity than did those with fewer stem cell
markers. The enhanced autophagy enabled CSCs to
survive under hypoxic stress [32]. Consistent with these re-
ports, we observed that pancreatic CSCs exhibited elevated
autophagy in both clinical specimens and cell lines. Block-
ade of autophagy by pharmacological or genetic inhibitors
reduced CSC populations, sphere-forming ability, drug re-
sistance, and tumor formation, revealing the requirement
of autophagy for pancreatic CSC maintenance. Therefore,
autophagy may act as a pro-survival regulator for pancre-
atic CSCs; however, the detailed mechanism is unclear.
Similar to normal stem cells, CSCs have the ability to
self-renew and differentiate through activation of several
embryonic stem cell signaling pathways, including Wnt/β-
catenin, Notch, and Hedgehog [33, 34]. In our study, when
autophagy-related genes were knocked down in pancreatic
cancer cells, β-catenin and Sonic Hedgehog expression was
significantly decreased but Notch1 expression was not
(Additional file 6: Figure S6), suggesting that autophagymay regulate pancreatic CSC activity by modulating Wnt/
β-catenin and Hedgehog signaling.
Currently, CD44, CD133, and ALDH1 are the most
commonly used markers in identification of pancreatic
CSCs [35]. These markers, however, are not universal
and perfect to identify CSCs because not all CSCs
express the markers, and non-CSCs may also exhibit the
markers. Therefore, the markers can be used for identifi-
cation of CSC-rich subpopulations but not for unam-
biguous isolation of all of the CSCs. Likewise, autophagy
may not be exclusively activated in CSCs but also in
non-CSCs of pancreatic cancer. These may be the causes
of the weak correlation between autophagy and single
CSC marker expression (CD44 or CD133) in pancreatic
tumor tissues. Since there is a partial overlap between
CD44+/CD24+/ESA+ and CD133+ pancreatic cancer cells
[6], it is conceivable that a combination of the markers
may help to mark more pure CSCs than a single marker.
Indeed, our group found that CD44+/CD133+ cells iso-
lated from PANC-1 cells were capable of forming
tumorspheres in vitro, exhibited tumor-initiating poten-
tials in vivo, and profoundly responded to Wnt pathway
activation or inhibition [36]. Accordingly, in our in vitro
experiments, we used CD44 in combination with CD133
to identify a CSC population. We observed that the
number of CD44+CD133+ cells was increased by the
autophagy inducer rapamycin but was decreased by the
autophagy inhibitor CQ or knockdown of autophagy-
related genes, revealing the requirement of autophagy
for the maintenance of CD44+CD133+ cells in pancreatic
cancer. Unlike CD44 and CD133, ALDH1 showed a high
correlation with LC3 expression in pancreatic tumors.
This may be because ALDH1 expression and autophagy
activation are regulated by some common signaling
pathways. ALDH1 reportedly is a target gene of the NF-
κB pathway [37–39]. Together with our observation that
OPN triggered autophagy by activating NF-κB, the NF-
κB pathway may act as an upstream positive regulator of
both ALDH1 and autophagy in pancreatic cancer cells.
However, further investigation is needed to substantiate
our speculation.
The efficacy of current available therapeutic methods
against pancreatic cancer remains limited. Gemcitabine
is the standard chemotherapy used as first-line treatment
Fig. 3 (See legend on next page.)
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Fig. 3 Pharmacological inhibition of autophagy reduces pancreatic CSC activity. a The expression of LC3, ALDH1, CD44, and CD133 in PANC-1
cells after 24 h of CQ, rapamycin (Rapa) and combination treatment was analyzed by flow cytometry. The graphs indicate the percentage ± SE of
LC3+/ALDH1+ cells (upper) and CD44+/CD133+ cells (lower). b The enzymatic activity of ALDH1 in PANC-1 cells after 24 h of CQ, Rapa, and
combination treatment was measured by ALDEFLUOR assay. The graph indicates the percentage ± SE of ALDEFLUOR+ cells in PANC-1 cells.
c The bright field images reveal the sphere formation of PANC-1 cells after 14 days of culture in ultra-low attachment plates with CQ, Rapa,
and combination treatment. The number of spheres was calculated and presented as mean ± SE. NS, not significant; *, P < 0.05; **, P < 0.01;
***, P < 0.001 compared to controls
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the survival extension is only marginal [40, 41]. The high
incidence of tumor relapse following treatment is be-
lieved to be caused by the presence of residual CSCs that
are resistant to conventional therapies [42]. Impairment
of CSC activity has been reported to reverse gemcitabine
resistance [43, 44]. In this study, gemcitabine alone
showed low efficacy in eliminating pancreatic CSCs and
preventing xenograft tumor formation. However, block-
ade of autophagy by genetic knockdown or autophagy
inhibitor CQ sensitized pancreatic CSCs to gemcitabine
and thus almost eradicated xenograft tumors in mice.
Our results are in good agreement with a previous study
reporting that autophagy exerts a cytoprotective effect
against chemotherapy drugs 5-FU and gemcitabine in
pancreatic cancer cells, and inhibition of autophagy by
CQ potentiated the growth-inhibitory effects of 5-FU
and gemcitabine [18]. These findings highlight the excit-
ing possibility that gemcitabine in combination with
drugs that inhibit autophagy evokes a synergistic antitu-
mor effect for pancreatic cancer treatment. Notably, a
recent study demonstrated that CQ can counteract pri-
mary pancreatic CSC activity through inhibition of
CXCR4 and Hedgehog signaling but independent of au-
tophagy blockade, which is inconsistent with our result
that, in primary pancreatic tumor SP-1 cells, CQ caused
the accumulation of LC3 puncta, indicative of autophagy
inhibition (Additional file 4: Figure S4A). CQ has also
been reported to exert its actions not through inhibition
of autophagy but through impairment of lysosomal func-
tions [45]. Therefore, whether CQ-mediated inhibition
of pancreatic CSC activity depends on its ability to block
autophagy needs further confirmation.
OPN showed a positive association with coexpression
of CD44/CD133 or LC3/ALDH1 in pancreatic tumors in
this study; however the correlation was not strong. It is
known that OPN exerts its biological functions through
interaction with the integrin and CD44 families of cell
surface receptors [20]. OPN-mediated functions may be
determined by the different receptors. Therefore, ana-
lysis of OPN expression in combination with associated
receptor expression in pancreatic cancer cells may be
more appropriate to evaluate the correlation between
OPN signaling and CSC activity than only OPN detec-
tion. Previously, OPN has been reported to stimulateautophagy in vascular smooth muscle cells [25]. We here
found that OPN could also trigger autophagy via NF-κB
in pancreatic cancer cells, and this finding is supported by
several studies showing that NF-κB can act as an inducer
of autophagy. For instance, autophagy was induced by
NF-κB for cell survival during the heat shock response
[46]. Upon hypoxia, ROS-activated NF-κB can trigger au-
tophagy in breast cancer cells [47]. Intriguingly, autophagy
seemed to be enhanced by the JAK2/STAT3 inhibitor
AG490 in PANC-1 cells. Recently, STAT3 has been re-
ported to suppress LC3 expression, thereby inhibiting au-
tophagy and growth of pancreatic cancer cells [48].
Therefore, whether AG490 induces autophagy by inhibit-
ing STAT3 activity or through its unknown off-target ef-
fects remained to be clarified.
Conclusions
In this study, we provide evidence that OPN/NF-κB-
mediated autophagy is required for pancreatic CSC main-
tenance, suggesting OPN/NF-κB/autophagy as an attract-
ive target for eliminating pancreatic CSCs. Gemcitabine
chemotherapy may offer greater therapeutic benefits to
pancreatic cancer patients in combination with drugs
against autophagy.
Methods
Cell lines and culture conditions
Human pancreatic cancer cell lines PANC-1, MIA PaCa-2,
and AsPC-1 were obtained from American Type Culture
Collection. All the cell lines and their derived cells were
maintained in RPMI 1640 medium (Hyclone, SH30027.02)
with 10 % fetal bovine serum (Invitrogen). Cells were
incubated at 37 °C in a humidified atmosphere containing
5 % CO2.
Isolation of primary tumor cells
Primary pancreatic tumor SP-1 cells were collected from
the centrifugal sedimentation of ascites obtained from a
50-year old male patient. The histopathological examination
of the patient’s tumor tissue revealed a well-differentiated
ductal adenocarcinoma of the pancreas. Briefly, the bulk of
ascites cells were seeded on culture flasks containing RPMI
1640 medium (Hyclone, SH30027.02) with 10 % fetal
bovine serum (Invitrogen), 2 mM L-glutamine and 1 %
penicillin/streptomycin (Caisson) at 37 °C in a humidified
Fig. 4 (See legend on next page.)
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Fig. 4 Blockade of autophagy by genetic knockdown suppresses tumor formation and sensitized pancreatic CSCs to gemcitabine. a The control,
shATG5, shATG7 and shBECN1 cells were cultured for 48 h. Cell growth was analyzed by MTT assay (left panel). The percentages of apoptotic
cells were determined by annexin V staining using flow cytometry (right panel). b The control, shATG5, shATG7, and shBECN1 cells were
subcutaneously inoculated into the flanks of NOD/SCID mice. Each group contained 5 mice. The tumor volume was measured once weekly
for 8 weeks, and the tumor weight was measured at the end of the experiment. c The bulk cells and the sphere-forming cells from the
control, shATG5, shATG7 and shBECN1 cells were treated with gemcitabine for 48 h. The viability of the cells was determined by MTT assay.
d The control, shATG5, shATG7, and shBECN1 cells were subcutaneously inoculated into the flanks of NOD/SCID mice. When the tumor
volume reached 62.5 mm3, gemcitabine (GEM) was given intraperitoneally to mice at a dosage of 100 mg/kg once weekly for 4 weeks. e PANC-1 cells
were subcutaneously inoculated into the flanks of NOD/SCID mice. When the tumor volume reached 62.5 mm3, mice were injected intraperitoneally with
GEM (100 mg/kg), CQ (60 mg/kg), and their combination once weekly for 4 weeks. The tumor volume was measured every week after the first injection
of each agent. The tumor weight in the lower panel was measured at the end of the experiment. Each group contained 3 mice. Values represent
means ± SE. NS, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001, significant differences between groups
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stellate cells were removed by two rounds of serial enzym-
atic detachment with 0.05 % Trypsin/ EDTA (Life Tech-
nologies). The resulting population of cells was confirmed
as cancer cells by tumor formation assay in vivo. For the ex-
periments described here, SP-1 cells were used in passages
8 to 12. Immortalization of the isolated tumor cells was not
necessary.
Sphere formation and CSC harvest
Cells were seeded into 6-well ultra-low attachment plates
(Corning, 3471) at a density of 4 × 104 cells/well with
serum-free medium containing 10 ng/mL basic FGF
(PeproTech, 100-18B), 20 ng/mL EGF (PeproTech,
AF-100-15), insulin-transferrin-sodium selenite media
supplement (Sigma-Aldrich, 3116), and 0.4 % bovine serum
albumin (Sigma-Aldrich, A7030). After 14 days of culture,
the number of spheres was counted and the spheres were
disaggregated into single cells with accutase (Invitrogen,
A11105-01). The viable cells were counted by Eosin Y
(Sigma-Aldrich, 230251) and cultured for further use.
Measurement of cell viability
The growth or viability of cells was assessed with MTT
reagent (Sigma-Aldrich, M2003). Cells were seeded into
96-well plates at a density of 4 × 103/well. After treat-
ments, MTT was added to each well (final concentra-
tion of 0.5 mg/mL) followed by incubation at 37 °C for
4 h. The supernatant was removed, and DMSO was
added to dissolve the blue-purple crystals of formazan.
The optical density of the samples was measured at a
wavelength of 540 nm by spectrophotometer (Thermo
Scientific, Multiskan EX).
CSC identification and apoptosis detection
For CSC identification, 2 × 105 cells were stained for
ALDH1, CD44, and CD133 (antibodies are listed in
Additional file 7: Table S1). After washing with PBS,
cells were analyzed by flow cytometry (FACS Canto II).
For detection of apoptosis, specific binding of Annexin
V to phosphatidylserine was performed by incubatingthe cells in binding buffer containing a saturating con-
centration of Annexin V-FITC (BD Biosciences, 556547)
according to the manufacturer’s protocol. Following in-
cubation, cells were pelleted and analyzed by flow
cytometry.
Tumor formation in NOD/SCID mice and chemoresistance
test
1 × 106 cells were subcutaneously inoculated into the
right flank of 8-week old male NOD/SCID mice to form
tumors. When the size of individual tumor reached
5 mm in diameter, animals were injected intraperitone-
ally with gemcitabine (100 mg/kg), CQ (60 mg/kg), and
their combination once weekly for 4 weeks. Tumor
volume was measured every week at the beginning of
treatments using the formula: volume = a2 × b/2 where a
is the major diameter and b is the minor diameter verti-
cal to a. Animals were raised and cared for according to
the guidelines set up by the National Science Council,
ROC. The animal experiments were approved by the
Institutional Animal Care and Use Committee.
Lentiviral transduction and stable cell line generation
OPN, ATG5, ATG7, BECN1, and non-target short
hairpin RNA (shRNA) vectors were purchased from the
National RNAi Core Facility, Academia Sinica. Both
plasmids pMD.2G and psPAX2 for lentiviral packaging
were kind gifts from Dr. Mettling Clément (Institut de
Génétique Humaine, CNRS UPR1142, Montpellier,
France). The lentiviral particles were made by transfecting
above-mentioned plasmids into 293 T cells and collected
at 48 h post transfection. PANC-1 and MIAPaCa-2 cells
were infected in the presence of 4 μg/mL polybrene
(Sigma-Aldrich, AL-118). Puromycin (Sigma-Aldrich,
P9620) was used for drug selection of infected cells to
generate permanent cell lines.
ALDEFLUOR assay
ALDH1 activity was detected by ALDEFLUOR assay kit
(Stem Cell Technologies, 01700) according to manufac-
turer’s protocol. Briefly, cells were incubated in Aldefluor
Fig. 5 (See legend on next page.)
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Fig. 5 OPN upregulates pancreatic CSC activity by activating autophagy. a PANC-1 cells were treated with or without OPN (100 ng/mL) for
24 h. The lysates were collected for Western blotting using the indicated antibodies. b The lysates of PANC-1 cells with or without stable
expression of OPN-specific shRNA were subjected to Western blotting using the indicated antibodies. c The control, shATG5, shATG7,
shBECN1 cells were treated with OPN (100 ng/mL) for 24 h. The lysates were collected for Western blotting with the indicated antibodies.
d and e PANC-1 cells were pretreated with the JAK2/STAT3 inhibitor AG490 (40 μM), the MEK/ERK inhibitor PD98059 (5 μM), and the NF-κB
inhibitor BAY 1170–82 (5 μM) for 1 h followed by incubation with OPN (100 ng/mL) for 24 h. The lysates were subjected to Western blotting
using LC3 antibodies. The number of LC3+/ALDH1+ cells and CD44+/CD133+ cells was measured by flow cytometry. Values represent means
± SE. NS, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared to controls
Fig. 6 OPN/LC3/ALDH1 coexpression and OPN/CD44/CD133 coexpression are associated with poor patient survival. a Pancreatic cancer tissues were
triplestained for OPN (blue), LC3 (red), and ALDH1 (green) (upper panel), and triplestained for OPN (blue), CD44 (red), and CD133 (green) (lower panel). The
staining was visualized by confocal microscopy. Magnification: 400×, scale bar: 20 μm. b Immunofluorescence staining of OPN, LC3, ALDH1, CD44, and
CD133 was performed in TMAs. OPN expression was positively correlated with LC3/ALDH1 coexpression (R= 0.354, P< 0.001) and CD44/CD133
coexpression (R= 0.211, P= 0.042). c Kaplan–Meier analysis showed that high levels of OPN/LC3/ALDH1 were associated with worse OS and DFS (P= 0.029
and P= 0.009). d Kaplan–Meier survival curves showed that high levels of OPN/CD44/CD133 were associated with worse OS and DFS (P<0.001 and P<0.001)
Yang et al. Molecular Cancer  (2015) 14:179 Page 14 of 17
Yang et al. Molecular Cancer  (2015) 14:179 Page 15 of 17assay buffer containing ALDH1 substrate bodipy-
aminoacetaldehyde (1 μmol/L per 1 × 106 cells) at 37 °C for
50 min. As a negative control, a fraction of cells from each
sample was incubated under identical condition in the
presence of ALDH1 inhibitor diethylaminobenzaldehyde
(15 μmol/L per 0.5 × 106 cells). The cells were then sub-
jected to FACS analysis.
Cell lysis and Western blot analysis
The harvested cells were lysed in ice for 30 min with
lysis buffer (Cell Signaling Technology, 9803). Lysates
were cleared by centrifugation at 14,000 rpm for 10 min
at 4 °C. Protein concentrations were measured by the
Bradford assay (Bio-Rad Laboratories, 500–0006). For
Western blot analysis, cell lysates were boiled for 5 min
with sample buffer before being resolved in SDS–poly-
acrylamide gels. The proteins were transferred to PVDF
membrane (Millipore, IPVH00010). The membrane was
blocked with 5 % skim milk in TBST buffer (20 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 0.1 % Tween 20) for one hour
and then stained with primary antibodies at 4 °C overnight
followed by incubation with secondary antibodies (anti-
bodies are listed in Additional file 7: Table S1). The binding
of each antibody was detected using an enhanced chemi-
luminescence kit (PerkinElmer, NEL105001EA). The signals
were detected by X-ray films (Fuji, 47410 08399) or a UV
transilluminator (UVP Ltd., BioSpectrum™ 500 Imaging
System) and analyzed by the Gel-Pro Analyzer 4.0 software
(Media Cybernetics).
Immunofluorescence staining and analysis of clinical
samples
A total of 93 pancreatic cancer patients who underwent
resection in National Cheng Kung University Hospital
(NCKUH) were included in this study that was approved
by Institutional Review Board of NCKUH. Anonymous ar-
chived samples of human pancreatic cancer, including
both normal and malignant tissues, were obtained from
Human Biobank of NCKUH for TMA construction.
Paraffin-embedded TMAs were cut into 5 μm-thick
sections and stained with primary antibodies (listed in
Additional file 7: Table S1) at 4 °C overnight followed by
incubation with secondary antibodies (listed in Additional
file 7: Table S1) at room temperature for 1 h. Cell nuclei
were counterstained with DAPI (blue; Molecular Probes,
D3571) or DRAG5 (purple; Abcam, ab108410). Fluores-
cence imaging was performed using a laser scanning
confocal microscope (Olympus, Fluoview 1000), and the
signals were quantified with Tissue-Quest software. The
percentage of protein staining for each tumor specimen
was classified into two staining grades according to the
mean value of protein expression (the high grade repre-
sents ≥mean; the low grade represents <mean). Tumor
heterogeneity was evaluated using Pearson correlationcoefficients (r) in two different cores from the same tumor
blocks, as described previously [49].Statistics
Data are expressed as means ± SE from three independent
experiments. Statistical analysis in this article was per-
formed by one- or two-way ANOVA using Prism 5.0
software. The median survival was estimated using the
Kaplan-Meier method. The association between studied
variables was evaluated using Pearson’s correlation coeffi-
cient test in SPSS 17.0. Significance was set at P < 0.05.
Supplementary Materials and Methods are available as
Additional file 8.Additional files
Additional file 1: Figure S1. Autophagy is activated in pancreatic CSCs.
(A) Pancreatic tumor tissues were immunofluorescently stained for LC3
(green), LAMP1 (red), and SQSTM1/p62 (red). Images were taken at 800×
magnification, and white scale bar indicates 20 μm. (B) Autophagosome-like
double-membrane structures in the sphere-forming cells and the bulk cells
from PANC-1 cells were visualized by transmission electron microscopy.
Magnification: 10,000×, Scale bar: 2 μm. Images on the lower panel are
high-magnification of the areas outlined by red squares. The bar graph
indicates the means ± SE of the number of autophagosome-like
double-membrane vesicles per cell counted on at least 20 cells.
*, P<0.05, vs. bulk cells. (For detail, please see Additional file 8). (TIFF 3054 kb)
Additional file 2: Figure S2. Pancreatic CSCs enriched by sphere
formation exhibit increased chemoresistance and anti-apoptotic activity.
PANC-1, MIA PaCa-2, AsPC-1, and SP-1 cells were cultured in ultra-low
attachment plates for 14 days to form spheres. The bulk cells and the
sphere-forming cells were treated with gemcitabine for 48 h. (A) The
viability of the cells was analyzed by MTT assay. (B) The percentages of
apoptotic cells were determined by annexin V/PI staining. The Values
represent means ± SE. *, P<0.05; **, P<0.01; ***, P<0.001, vs. bulk cells.
(TIFF 1784 kb)
Additional file 3: Figure S3. Neither LC3 nor ALDH1 expression shows
significant correlation with patient outcomes. (A) Kaplan–Meier analysis
showed that LC3 expression was not associated with both OS and DFS of
patients (P = 0.593 and P = 0.840). (B) Kaplan–Meier analysis showed that
ALDH1 levels were not associated with both OS and DFS (P = 0.897 and
P = 0.898). (TIFF 1956 kb)
Additional file 4: Figure S4. Knockdown of OPN inhibits CSC activity,
cell growth, and tumor formation, but promotes apoptosis. (A) PANC-1,
MIA PaCa-2, and SP-1 cells were treated with OPN (100 ng/mL), CQ
(15 μM), or their combination for 24 h followed by being stained with
antibodies against LC3 and ALDH1, and then were visualized by confocal
microscope (original magnification: 200×, scale bar: 50 μm). The images
on the lower are high-magnification of the areas outlined by white
squares. Scale bar: 20 μm. (B) The non-silenced control cells and cells
permanently expressing OPN-specific shRNA (shOPN cells) derived from
PANC-1 and MIA PaCa-2 cells were cultured in ultra-low attachment
plates for 14 days to form spheres. The number of spheres was calculated
and presented as means ± SE. (C) The control and shOPN cells derived
from PANC-1 and MIA PaCa-2 were cultured for 48 h. The growth of the
cells was analyzed by MTT assay (left panel). The control and shOPN cells
were grown for 48 h. The percentages of apoptotic cells were determined
by annexin V/PI staining using flow cytometry (right panel). (D) The control
and shOPN cells were subcutaneously inoculated into the flanks of NOD/
SCID mice. Each group contains 5 mice. The tumor volume was measured
once per week for 4 weeks, and the tumor weight was measured at the
end of the experiment. All results represent mean ± SE. NS, not significant;
*, P<0.05; **, P<0.01; ***, P<0.001 compared to control cells. (TIFF 3302 kb)
Yang et al. Molecular Cancer  (2015) 14:179 Page 16 of 17Additional file 5: Figure S5. OPN triggered STAT3, ERK, and NF-κB
activation, but not AKT, JNK, and p38 MAPK in pancreatic cancer cells.
(A) PANC-1 and MIA PaCa-2 cells were treated with OPN (100 ng/mL) for
the indicated time points. The cell lysates were prepared and subjected
to Western blotting using the indicated antibodies. (B) PANC-1 and MIA
PaCa-2 cells were incubated with OPN (100 ng/mL) for the indicated time
points. Cells were lysed and fractionated, and the levels of NF-κB p65 in
both cytosolic and nuclear fractions were detected by Western blotting.
β-Actin serves as a cytosolic marker, and LAMIN A/C serves as a nuclear
marker. (For detail, please see Additional file 8). (TIFF 2417 kb)
Additional file 6: Figure S6. The β-Catenin and Sonic hedgehog signaling
pathways are involved in regulation of pancreatic CSC activity by autophagy.
The cell extracts were prepared from the control, shATG5, shATG7 and
shBECN1 cells and subjected to Western blotting with the indicated
antibodies. (TIFF 1146 kb)
Additional file 7: Table S1. List of antibodies used in this study.
(DOCX 20 kb)
Additional file 8: Supplementary Materials and Methods.
(DOCX 17 kb)
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